Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients

BACKGROUND: Dolutegravir is a powerful, well-tolerated integrase inhibitor with a high genetic barrier to resistance and may thus constitute the backbone of lightened regimens. METHODS: This was a monocentric, retrospective study. HIV-1-infected patients receiving dolutegravir as monotherapy (mDGV)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Antimicrob Chemother
Main Authors: Gubavu, Camelia, Prazuck, Thierry, Niang, Mohamadou, Buret, Jennifer, Mille, Catherine, Guinard, Jérôme, Avettand-Fènoël, Véronique, Hocqueloux, Laurent
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4790618/
https://ncbi.nlm.nih.gov/pubmed/26712907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkv430
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados